January 2026 FDA New Drug Approvals Zycubo (copper histidinate) Some approvals mark progress. Others redefine what hope looks like. In January 2026, the U.S. FDA approved Zycubo (copper histidinate injection formerly The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what BREAKING NEWS: HHS @seckennedy just announced that the FDA is taking a step toward restoring science based access by removing 12 peptides from Category 2. FDA is moving them to an independent scientific GHK Cu GHK Cu FDA Approval Status 2026: Not Approved